This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Introduction:Reducing door-to-needle (DTN) times lead to improved patient outcomes in acute ischemic stroke. 2) Creation of a multidisciplinary Thrombolysis Focus Group to analyze data and improve processes. 2) Creation of a multidisciplinary Thrombolysis Focus Group to analyze data and improve processes. in 2020, to 31.9%
The role of adjunctive intravenous thrombolysis, such as intravenous tissue plasminogen activator (IVtPA), with MT remains unclear, especially for medium vessel occlusion (MeVO). In univariable regression, all outcomes were comparable between the two groups, except for higher mRS 0-2 rates in the MT+IVtPA group.
Introduction:Recent studies report similar outcomes with antiplatelet drugs and intravenous thrombolysis (IVT) in patients with minor nondisabling ischemic stroke. Stroke, Volume 55, Issue Suppl_1 , Page ATMP13-ATMP13, February 1, 2024. Patients were excluded if they were on anticoagulation, presented beyond 4.5
Background:Every minute is crucial in treating acute ischemic stroke (AIS), as the effectiveness of intravenous thrombolysis and endovascular therapy is highly time-dependent. Stroke, Volume 56, Issue Suppl_1 , Page AWP70-AWP70, February 1, 2025.
BACKGROUND:The aim of this study was to examine the impact of early versus delayed catheter-based therapies (CBTs) on clinical outcomes in patients with acute intermediate-risk pulmonary embolism (PE).METHODS:This Secondary outcomes included a composite of 30-day mortality, resuscitated cardiac arrest, and hemodynamic instability.
It is a sad academic story ,most of the interventional cardiology community shrugged it off as a non-event. In this context, we need a movement to revive the pre-hospital thrombolysis. No one knows how the pPCI related delay was legally ratified and academically accepted by the elite cardiology forums.
Introduction:Outcomes after thrombolysis with alteplase (tPA) versus tenecteplase (TNK) prior to endovascular thrombectomy (EVT) have not been directly compared in real-world data (RWD). tPA was used exclusively for thrombolysis at one center (n=74), while TNK was used exclusively for thrombolysis at another center (n=130).
A combined effort from academic investigators, industry, and regulators is needed to improve imaging technologies and, ultimately, patient outcomes. Imaging in acute ischemic stroke treatment has advanced significantly, but important challenges remain that need to be addressed.
We characterized rates of technical success achieved using this technique for mechanical aspiration thrombectomy.METHODSA retrospective review of prospectively collected thrombectomy databases at 4 academic institutions identified patients undergoing procedures in which AO‐ADAPT was used. female; 71.1% M1 occlusions).
Our academic comprehensive stroke center transitioned from Alteplase to Tenecteplase as standard thrombolysis for acute ischemic stroke in November 2022. Further review is necessary to evaluate additional stroke metrics and clinical outcomes. There was no significant difference in mean door-to-needle time (59.27 Alteplase vs 53.09
One patient was also found eligible and treated with IV-thrombolysis. We review the results of 9 patients who were evaluated with digital subtraction angiography (DSA), including 2 patients receiving different multiple drug regimens of acute intra-arterial therapies.
We evaluated whether utilizing an APP in the emergency room affected timing and safety of IV thrombolytic therapy.Methods:Single center academic hospital retrospective analysis on acute ischemic stroke patients given thrombolytic therapy in the emergency department between January 2022 and June 2024. Patients treated greater than 4.5
Some receive intravenous thrombolysis (IVT) before transfer, while others are transferred for further evaluation and possibly treatment at the CSC. An initial NIHSS score is assigned upon initial evaluation by by NIHSS-certified EMS and MSU first responders, or emergency department providers.
The open-data movement seeks to liberate the massive amount of data generated in running clinical trials from the grasp of the academic medical-pharmaceutical industrial complex that mostly runs the most important trials responsible for bringing novel therapeutics to market. But first, some background.
The Times also briefly touches on some other patients of Mustapha who had bad outcomes. A thrombolysis is performed in the hospital via a catheter. Academics, especially, are hostile to all work being done outsie their purview. The procedures were unsuccessful, and Ms. Hanna ultimately did need an amputation. 4.8.2017. .”
Here is evidence for this: Opiates are associated with worse outcomes in Myocardial Infarction. Association of intravenous morphine use and outcomes in acute coronary syndromes: Results from the CRUSADE Quality Improvement Initiative. Academic Emergency Medicine 27(S1): S220; May 2020. Am Heart J. 2005;149:10431049.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content